Ad
related to: genentech access solutions patient assistance portal registration application
Search results
Results From The WOW.Com Content Network
For people with insurance, Genentech Access Solutions offers co-pay assistance programs to help with the out-of-pocket costs of their medicine, including a co-pay card for those with private ...
FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer -- New Personalized Medicine Helped People in ...
Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including Cetus Corporation which was founded in 1971.
Trastuzumab. Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [20] [17] [21] [22] It is specifically used for cancer that is HER2 receptor positive. [20] It may be used by itself or together with other chemotherapy medication. [20]
Endrov Image and data viewer and editor. It is available under the BSD license. [40] GIMIAS is a workflow-oriented environment focused on biomedical image computing and simulation. It is available under a BSD-style license. [41] Ginkgo CADx Cross-platform open source DICOM viewer and dicomizer.
FDA Files Genentech's Supplemental Biologics License Application of Xolair ® (omalizumab) for Chronic Idiopathic Urticaria (CIU) CIU is a skin condition characterized by red, swollen, itchy hives ...
The Patient Access Network Foundation (PAN Foundation) is a US-based non-profit 501(c)(3) organization that works to help Americans pay for medical procedures. The organization was ranked #34 in Forbes ' 2019 list of "top 100 US Charities", with private donations in 2019 totaling $434 million. [1]
At Lund University in Sweden, researchers have found that a new blood test called PrecivityAD2 is about 90% accurate in identifying Alzheimer’s disease in people experiencing cognitive symptoms ...
Ad
related to: genentech access solutions patient assistance portal registration application